About Superluminal Medicines
Superluminal Medicines is a company based in Boston (United States) founded in 2022 by Ajay Yekkirala and Cony Dcruz. Superluminal Medicines has raised $158 million across 3 funding rounds from investors including Lilly, Nvidia and RA Capital. Superluminal Medicines offers products and services including Generative Biology Platform and Chemistry Design Tools. Superluminal Medicines operates in a competitive market with competitors including Evotec, Crown Bioscience, Alloy Therapeutics, Domainex and NIH, among others.
- Headquarter Boston, United States
- Founders Ajay Yekkirala, Cony Dcruz
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Superluminal Medicines, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$158 M (USD)
in 3 rounds
-
Latest Funding Round
$5 M (USD), Series A
Aug 14, 2025
-
Investors
Lilly
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Superluminal Medicines
Superluminal Medicines offers a comprehensive portfolio of products and services, including Generative Biology Platform and Chemistry Design Tools.
AI platform for designing and testing drug compounds quickly.
Tools for modeling protein shapes and selective compound creation.
People of Superluminal Medicines
Unlock access to complete
Leadership Team
2 people
Senior Team
1 people
Product Management Team
1 people
Sales and Marketing
1 people
Unlock access to complete
Funding Insights of Superluminal Medicines
Superluminal Medicines has successfully raised a total of $158M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Superluminal Medicines
Superluminal Medicines has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Nvidia and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment firm scaling software and technology companies from early to late stages.
|
Locked | Locked | Locked | |
|
Venture capital investing with a focus on diversity and inclusion in the ecosystem.
|
Locked | Locked | Locked | |
|
Venture capital is provided to biomedical technology startups.
|
Locked | Locked | Locked |
Investor details for Superluminal Medicines
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Superluminal Medicines
Investment portfolio details for Superluminal Medicines
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Superluminal Medicines
Detailed financials for Superluminal Medicines
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Superluminal Medicines Comparisons
Peer comparison for Superluminal Medicines
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Superluminal Medicines
Superluminal Medicines operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evotec, Crown Bioscience, Alloy Therapeutics, Domainex and NIH, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery and development services are provided to biopharma sector.
|
|
| Locked | Locked | Locked |
Cancer and CVMD drugs are developed using PDX models.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided for therapeutic development.
|
|
| Locked | Locked | Locked |
Drug discovery CRO company for epigenetic research and inflammatory diseases
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to the biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to pharmaceutical clients worldwide.
|
Detailed competitors of Superluminal Medicines
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Superluminal Medicines
Complete news archive for Superluminal Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Superluminal Medicines
Superluminal Medicines was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Superluminal Medicines is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Cony Dcruz is the current CEO of Superluminal Medicines. They have also founded this company.
Superluminal Medicines is a funded company, having raised a total of $158M across 3 funding rounds to date.
Superluminal Medicines Inc. was established in 2022 in Boston, Massachusetts, United States, within the biotechnology sector. Generative biological and chemical approaches are employed for drug discovery programs, with a focus on small molecule therapeutics. A pipeline is advanced through these methods, bolstered by a 33 million seed funding round obtained recently. Research operations center on developing solutions for pharmaceutical applications.
Superluminal Medicines's top competitors include Evotec, Crown Bioscience and NIH.
Superluminal Medicines offers Generative Biology Platform and Chemistry Design Tools.
Superluminal Medicines has 7 investors. Key investors include Lilly, Nvidia, RA Capital, Cooley, and Insight Partners.